A5020466963- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Respiratory viral infections research
- interferon and immune responses
- Mosquito-borne diseases and control
- Herpesvirus Infections and Treatments
- Influenza Virus Research Studies
- Viral Infections and Vectors
- Plant Virus Research Studies
- HIV/AIDS drug development and treatment
University of Rochester Medical Center
2016-2018
Universidade Nova de Lisboa
2015
University of Nevada, Reno
2012
PA-X is a recently identified influenza virus protein that composed of the PA N-terminal 191 amino acids and unique C-terminal 41 or 61 residues. We others showed has strong ability to suppress host synthesis via mRNA decay, which mediated by endonuclease activity in its domain (B. W. Jagger, H. M. Wise, J. C. Kash, K. A. Walters, N. Wills, Y. L. Xiao, R. Dunfee, Schwartzman, Ozinsky, G. Bell, Dalton, Lo, S. Efstathiou, F. Atkins, E. Firth, Taubenberger, P. Digard, 2012, Science 337:199-204,...
The latency-associated nuclear antigen (LANA) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) plays a major role in maintaining latency and is critical for the perpetual segregation of viral episomes to progeny nuclei newly divided cells. LANA binds KSHV terminal repeat (TR) DNA tethers host chromosomes through association chromatin-bound cellular proteins. TR elements serve as potential origin sites replication have been shown play important roles latent transcription adjacent...
Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus responsible for the development of sarcoma, primary effusion lymphoma (PEL), and Multicentric Castlemann's disease in immunocompromised individuals. Despite burden these diseases there are few treatment options afflicted individuals, due part to our limited understanding virus-host interactions. Tip60, a histone aceytltransferase (HAT) has been previously shown interact with both KSHV latency associated nuclear antigen...